DE69930621D1 - Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung - Google Patents

Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung

Info

Publication number
DE69930621D1
DE69930621D1 DE69930621T DE69930621T DE69930621D1 DE 69930621 D1 DE69930621 D1 DE 69930621D1 DE 69930621 T DE69930621 T DE 69930621T DE 69930621 T DE69930621 T DE 69930621T DE 69930621 D1 DE69930621 D1 DE 69930621D1
Authority
DE
Germany
Prior art keywords
immediate release
oral use
medical compositions
hydrate
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69930621T
Other languages
English (en)
Other versions
DE69930621T2 (de
Inventor
Kiyohisa Ouchi
Kaoru Kaneko
Ken Kanada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69930621D1 publication Critical patent/DE69930621D1/de
Publication of DE69930621T2 publication Critical patent/DE69930621T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F16/00Information retrieval; Database structures therefor; File system structures therefor
    • G06F16/30Information retrieval; Database structures therefor; File system structures therefor of unstructured textual data
    • G06F16/31Indexing; Data structures therefor; Storage structures
    • G06F16/313Selection or weighting of terms for indexing
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F16/00Information retrieval; Database structures therefor; File system structures therefor
    • G06F16/80Information retrieval; Database structures therefor; File system structures therefor of semi-structured data, e.g. markup language structured data such as SGML, XML or HTML
    • G06F16/83Querying
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S707/00Data processing: database and file management or data structures
    • Y10S707/912Applications of a database
    • Y10S707/917Text
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S707/00Data processing: database and file management or data structures
    • Y10S707/953Organization of data
    • Y10S707/955Object-oriented
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S707/00Data processing: database and file management or data structures
    • Y10S707/99931Database or file accessing
    • Y10S707/99933Query processing, i.e. searching
DE69930621T 1999-05-21 1999-05-21 Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung Expired - Lifetime DE69930621T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1999/002669 WO2000071117A1 (fr) 1999-05-21 1999-05-21 Compositions medicinales a liberation immediate pour administration orale

Publications (2)

Publication Number Publication Date
DE69930621D1 true DE69930621D1 (de) 2006-05-18
DE69930621T2 DE69930621T2 (de) 2006-11-09

Family

ID=14235747

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69930621T Expired - Lifetime DE69930621T2 (de) 1999-05-21 1999-05-21 Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung

Country Status (15)

Country Link
US (3) US7166301B1 (de)
EP (1) EP1179342B1 (de)
KR (1) KR100594606B1 (de)
CN (1) CN1352558B (de)
AT (1) ATE321550T1 (de)
AU (1) AU782005B2 (de)
BR (1) BR9917315A (de)
CA (1) CA2373962C (de)
DE (1) DE69930621T2 (de)
DK (1) DK1179342T3 (de)
ES (1) ES2262320T3 (de)
MX (1) MXPA01011898A (de)
NO (1) NO329213B1 (de)
PT (1) PT1179342E (de)
WO (1) WO2000071117A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
AU2003244083A1 (en) * 2002-06-28 2004-01-19 Kissei Pharmaceutical Co., Ltd. Drug composition for prevention or inhibition of advance of diabetic complication
CA2490250A1 (en) * 2002-06-28 2004-01-08 Kissei Pharmaceutical Co., Ltd. Drug composition for blood sugar control
US6846497B2 (en) * 2003-01-30 2005-01-25 National Starch And Chemical Investment Holding Corporation Rapidly expanding starches with altered crystalline structure
CN1976696B (zh) * 2004-05-11 2010-10-06 橘生药品工业株式会社 用于预防或治疗脂质代谢异常的医药组合物
WO2008018371A1 (fr) 2006-08-08 2008-02-14 Kissei Pharmaceutical Co., Ltd. Comprimé à désagrégation orale ayant un goût amer masqué et son procédé de production
TWI503122B (zh) 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
KR102237799B1 (ko) 2012-11-14 2021-04-08 더블유.알. 그레이스 앤드 캄파니-콘. 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3818096A (en) * 1972-04-12 1974-06-18 Schering Corp Compositions of 1,2-dilower alkyl arylpyrazolium quaternary salts and method of lowering blood sugar levels with same
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US4916163A (en) * 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
WO1988003023A1 (en) * 1986-10-31 1988-05-05 Mitsubishi Chemical Industries Limited Drug composition for treating liver diseases and process for its preparation
JPS63115815A (ja) * 1986-10-31 1988-05-20 Mitsubishi Kasei Corp 肝疾患治療薬組成物
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
AU654331B2 (en) * 1991-03-30 1994-11-03 Kissei Pharmaceutical Co. Ltd. Succinic acid compounds
JP2686863B2 (ja) * 1991-04-25 1997-12-08 キッセイ薬品工業株式会社 新規なベンジルコハク酸誘導体
JPH05139973A (ja) * 1991-11-20 1993-06-08 Shin Etsu Chem Co Ltd ニフエジピン含有固形製剤の製造方法
US6075024A (en) * 1991-11-27 2000-06-13 Sepracor Inc. Methods for treating infection using optically pure (S)-lomefloxacin
JPH0776516A (ja) * 1993-09-06 1995-03-20 Toyobo Co Ltd 難溶性薬物含有製剤の製造方法
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
US6165512A (en) * 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents

Also Published As

Publication number Publication date
AU3850599A (en) 2000-12-12
DK1179342T3 (da) 2006-07-31
CA2373962A1 (en) 2000-11-30
ATE321550T1 (de) 2006-04-15
NO20015666D0 (no) 2001-11-20
US7160556B2 (en) 2007-01-09
CN1352558A (zh) 2002-06-05
EP1179342A4 (de) 2002-09-04
EP1179342B1 (de) 2006-03-29
KR20020015327A (ko) 2002-02-27
KR100594606B1 (ko) 2006-06-30
US7166301B1 (en) 2007-01-23
CA2373962C (en) 2009-02-24
US20040197400A1 (en) 2004-10-07
EP1179342A1 (de) 2002-02-13
NO20015666L (no) 2001-11-20
NO329213B1 (no) 2010-09-13
US7160555B2 (en) 2007-01-09
MXPA01011898A (es) 2002-06-21
PT1179342E (pt) 2006-07-31
BR9917315A (pt) 2002-07-30
ES2262320T3 (es) 2006-11-16
WO2000071117A1 (fr) 2000-11-30
CN1352558B (zh) 2012-06-13
AU782005B2 (en) 2005-06-30
US20040192755A1 (en) 2004-09-30
DE69930621T2 (de) 2006-11-09

Similar Documents

Publication Publication Date Title
EE200100558A (et) Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
BR9904998B1 (pt) derivados de hidroxamida do ácido 5-oxo-pirrolidina-2-carboxìlico e composição farmacêutica.
CY1110969T1 (el) 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
IL166748A0 (en) Pyrazole derivative medicinal composition containing the same medicinal use thereof and intermediatefor production thereof
NO20074657L (no) Nitrogenholdige aromatiske ringforbindelser
WO2004067550A3 (fr) Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
TW200716547A (en) Piperidin-4-yl-amide derivatives
IL169184A0 (en) Aromatic compounds as anti-inflammatory, immunomdulatory and anti-proliferatory agents
IL172290A0 (en) Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
DE69930621D1 (de) Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung
AU9233101A (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
ATE299705T1 (de) Metallphthalocyanin-analoge enthaltende antibakterielle zusammensetzungen
BR0306701A (pt) Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um sal
BRPI0417179A (pt) gentisato de amlodipina, método de preparar o mesmo e composição farmacêutica para tratamento de doenças cardiovasculares
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
EP1291349A4 (de) Malto-oligosaccharide und deren verwendung
TW200509941A (en) Pharmaceutical solution composition
PT102338A (pt) Derivados de tiazolidinodiona substituidos enantiomericamente enriquecidos e composicoes farmaceuticas que os contem

Legal Events

Date Code Title Description
8364 No opposition during term of opposition